Research in Review Focus on Ovarian Cancer
J Clin Pathways. 2022;8(4):8-11.
Progression-Free Survival Associated With Olaparib With or Without Cediranibvs Platinum-Based Chemotherapy in Women With High-Grade Ovarian Cancer
Study findings suggest that neither olaparib monotherapy or olaparib plus cediranib increased progression-free survival when compared with platinum-based chemotherapy in women with high-grade serous or endometroid ovarian cancer sensitive to such chemotherapy.
Qualitative Study Explores Olaparib Adherence Among Patients With Ovarian Cancer
Findings from a qualitative study at the Mayo Clinic suggest that patients with ovarian cancer are willing to adhere to oral olaparib therapy long term.
Genomic Assays Aid Individualized Treatment Decision-Making for HR–Positive, HER2–Negative Breast Cancer
Greater reliance on genomic assays has reduced the use of adjuvant chemotherapy in women with early-stage, HR–positive, HER2–negative breast cancer who are free of axillary node disease and at low genomic risk, according to a recent study.
Combining Chemo With Immunotherapy Does Not Improve OS in Patients with NSCLC
Adding chemotherapy to first-line durvalumab plus tremelimumab improved PFS, but not OS, compared to durvalumab plus tremelimumab alone in patients with NSCLC.
Real-World Experience With Bevacizumab for Newly Diagnosed Ovarian Cancer
Among patients with ovarian cancer who received first-line treatment with bevacizumab, clinical outcomes and tolerability are consistent in the real-world setting and clinical trials.
Experts Provide Algorithm for Use of Bevacizumab and PARP Inhibitorsin Patients With Newly Diagnosed, Advanced Ovarian Cancer
Avelumab and atezolizumab may have limited impact on the clinical outcome of patients with newly diagnosed ovarian carcinoma, according to recent study findings.
Biosimilar vs Referent Trastuzumab for the Neoadjuvant Treatmentof ERBB2–Positive Breast Cancer
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
